Enveric Biosciences to Participate in Upcoming Investor Conferences in March

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced that CEO David Johnson will speak at two virtual investor conferences in March 2021. The first is the M Vest and Maxim Group Emerging Growth Conference on March 18, 2021, and the second is the Benzinga Biotech Small Cap Conference on March 25, 2021, where he will present at 12:30 p.m. ET and participate in a panel discussion at 11:40 a.m. ET. The company focuses on developing cannabinoid medicines aimed at improving cancer patients' quality of life, addressing conditions like radiodermatitis and chemotherapy-induced neuropathy.

NAPLES, Fla., March 15, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will participate in two upcoming investor conferences in March:

• M Vest and Maxim Group Inaugural Emerging Growth Conference to be held virtually on Thursday, March 18, 2021. To attend the conference, register here
  
  
• Benzinga's Biotech Small Cap Conference to be held virtually on Thursday, March 25, 2021. Mr. Johnson will present at 12:30 p.m. ET. In addition to the corporate presentation, Mr. Johnson will participate on the panel The Natural Solutions: Cannabis & Cannabinoids at 11:40 a.m. ET. To attend the conference, register here.

For more information regarding the conference, or to schedule a one-on-one meeting with Enveric's management team, please contact KCSA Strategic Communications at EnvericBio@kcsa.com or your Maxim Group and Benzinga representatives directly.

About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
ckasunich@kcsa.com / rcona@kcsa.com

View original content:http://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-march-301246977.html

SOURCE Enveric Biosciences

FAQ

What investor conferences will Enveric Biosciences participate in March 2021?

Enveric Biosciences will participate in the M Vest and Maxim Group Emerging Growth Conference on March 18, 2021, and the Benzinga Biotech Small Cap Conference on March 25, 2021.

What is the date and time of David Johnson's presentation at the Benzinga Conference?

David Johnson will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 12:30 p.m. ET.

What topics will be discussed by David Johnson at the Benzinga Conference?

David Johnson will participate in a panel discussion titled 'The Natural Solutions: Cannabis & Cannabinoids' at 11:40 a.m. ET on March 25, 2021.

What is the main focus of Enveric Biosciences?

Enveric Biosciences develops novel cannabinoid medicines aimed at improving the quality of life for cancer patients, specifically targeting conditions like radiodermatitis and chemotherapy-induced neuropathy.